erdafitinib + abiraterone acetate

This combination therapy involves the pan-fibroblast growth factor receptor (FGFR) kinase inhibitor erdafitinib (Balversa) administered in conjunction with either abiraterone acetate or enzalutamide. It is currently being evaluated in a Phase II clinical trial led by the University of Washington for the treatment of double-negative prostate cancer (DNPC). DNPC is a specific phenotype of prostate cancer characterized by the absence of androgen receptor (AR) expression and neuroendocrine markers, often associated with resistance to standard hormonal therapies. Erdafitinib works by blocking the activity of FGFR1-4 proteins, which are frequently upregulated in DNPC and contribute to tumor growth and survival. Abiraterone acetate (a CYP17 inhibitor) and enzalutamide (an AR antagonist) are standard-of-care androgen signaling inhibitors. The investigational regimen aims to determine if the addition of FGFR inhibition can provide therapeutic benefit in patients with this aggressive prostate cancer subtype.

Brand names

BalversaZytigaXtandi

Other names

erdafitinib + enzalutamideBalversa + ZytigaBalversa + Xtandi